BDSX
Biodesix, Inc.
There isn't enough reported data to score BDSX yet.
BDSX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
BDSX's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
BDSX PE Valuation
BDSX has no meaningful PE right now: it lost money over the past year.
BDSX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect BDSX's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
BDSX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$5.16 | +$2.44 |
| Q2 2025 | -$5.40 | +$3.60 |
| Q1 2025 | -$5.40 | +$5.40 |
| Q4 2024 | -$6.60 | +$6.20 |
| Q3 2024 | -$7.60 | +$9.60 |
| Q2 2024 | -$9.00 | +$12.20 |
| Q1 2024 | -$10.80 | +$15.00 |
| Q4 2023 | -$12.80 | +$18.20 |
BDSX is still losing money, but far less than before: $5.16 per share over the past year, against $36.40 at its worst in early 2022.
BDSX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24M | +10% |
| Q2 2026 | $26.9M | +34% |
| Q1 2026 | $25.6M | +42% |
| Q4 2025 | $28.8M | +41% |
| Q3 2025 | $21.8M | +20% |
| Q2 2025 | $20M | +12% |
| Q1 2025 | $18M | +21% |
| Q4 2024 | $20.4M | +39% |
BDSX's revenue has grown year over year for 17 quarters in a row: $24M last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -25% | +7 points |
| Q2 2026 | -20% | +29 points |
| Q1 2026 | -24% | +27 points |
| Q4 2025 | -6.8% | +26 points |
| Q3 2025 | -32% | +15 points |
| Q2 2025 | -49% | -2.6 points |
| Q1 2025 | -51% | +24 points |
| Q4 2024 | -33% | +14 points |
BDSX's operating margin was −25% last quarter, up 7 points from the same quarter a year ago.
BDSX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.8M | +$1.2M |
| Q2 2026 | -$1.8M | +$4.9M |
| Q1 2026 | -$10.2M | -$1.6M |
| Q4 2025 | $692K | +$5.6M |
| Q3 2025 | -$8.9M | +$2M |
| Q2 2025 | -$6.6M | +$13.9M |
| Q1 2025 | -$8.7M | +$6.9M |
| Q4 2024 | -$4.9M | +$10.3M |
BDSX has burned cash in almost every quarter: −$19M over the past year, against −$29M the year before.
BDSX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.5% | +364K shares |
| 1 year | +45% | +3.3M shares |
| 3 years | +172% | +6.7M shares |
| 5 years | +701% | +9.3M shares |
BDSX has 11M diluted shares, up 45% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
BDSX Net Leverage
BDSX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BDSX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 13.2 | Oversold |
BDSX's weekly RSI is 33 (neutral) and its Stochastic is 13 (oversold).
BDSX PE vs Healthcare Sector
BDSX has no meaningful PE right now: it lost money over the past year.
BDSX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.2 | 54% below |
| 20 week MA | $23.0 | 57% below |
| 50 week MA | $16.8 | 42% below |
| 100 week MA | $14.2 | 31% below |
| 200 week MA | $23.1 | 58% below |
BDSX is in a downtrend: it's below all five of its weekly moving averages, and 58% below its 200-week average.
BDSX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $248.6 | $359.4 | +45% |
| 2021 | $359.4 | $92.0 | -74% |
| 2022 | $92.0 | $33.0 | -64% |
| 2023 | $33.0 | $36.8 | +12% |
| 2024 | $36.8 | $29.6 | -20% |
| 2025 | $29.6 | $6.82 | -77% |
| 2026 YTD | $6.82 | $9.79 | +44% |
BDSX is up 44% so far in 2026, after finishing lower in four of the previous six years.